103 results
Page 2 of 6
8-K
EX-99.1
z79jg14f2a
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
8-K
EX-99.1
kvwb8wt2ym1ati
10 Aug 22
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
mlbwvu52ybr1669
20 Jul 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:01am
8-K
EX-99.1
rdgoya38
10 May 22
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:01pm
8-K
EX-99.1
up4ta5 nudle3il
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
helms t5watp4b
30 Mar 22
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
shas v9wf
28 Mar 22
Soleno Therapeutics Announces Proposed Underwritten Public Offering
4:59pm
424B5
vuszncts3 cm55zc
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
mgsw3o3nv3
24 Jan 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:06am
8-K
EX-99.1
ulvdnenn1sdayla6ajh
10 Nov 21
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
4:16pm
424B5
f58 32cwdjcrgb1
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
t3yqp
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
EX-99.2
bvyyt1
15 Apr 21
Other Events
12:00am
8-K
EX-99.1
2kgpryj
8 Mar 21
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
4:01pm
8-K
EX-99.1
39q8plg
3 Mar 21
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year
4:01pm